Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants

Biochemical Pharmacology

Volumn 61, Issue 1, 2001, Pages 73-85

  Dos Santos El Bachá, Ramon ^a   Daval, Jean Luc ^a   Koziel, Violette ^a   Netter, Patrick ^a   Minn, Alain ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Apomorphine; Free radicals; Necrosis; Neurotoxicity; Protein adducts; Thiols

Indexed keywords

1,4 BENZOQUINONE; ACETYLCYSTEINE; ANTIOXIDANT; APOMORPHINE; CATECHOL DERIVATIVE; CYSTEINE; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; GLUTATHIONE; MELANIN; REACTIVE OXYGEN METABOLITE; SEMIQUINONE; THIOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GLIA CELL; NERVE CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TISSUE INJURY;

ANIMALS; ANTIOXIDANTS; APOMORPHINE; CELL SURVIVAL; CELLS, CULTURED; DNA; DNA DAMAGE; DOPAMINE AGONISTS; DRUG INTERACTIONS; ELECTROPHORESIS, AGAR GEL; NEUROGLIA; NEURONS; OXIDATION-REDUCTION; PROTECTIVE AGENTS; PROTEINS; RATS;

EID: 0035184877     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00524-4     Document Type: Article

References (52)

1. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA)
2. Oxidative mechanisms in nigral cell death in Parkinson's disease
3. Mitochondrial dysfunction in neurodegenerative disorders
4. Aging, energy, and oxidative stress in neurodegenerative diseases
5. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
6. Increased levels of hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
7. A generalized increase in protein carbonyls in the brain in Parkinson's but not in incidental Lewy body disease
8. Apoptosis, neurotrophic factors and neurodegeneration
9. Olfactory primary neurons as a route of entry for toxic agents into CNS
10. + produces progressive neuronal degeneration which is mediated by oxidative stress
11. Alloxan, and 6-hydroxydopamine, cellular toxins
12. Biochemical and toxicological properties of the oxidation products of catecholamines
13. Pharmacology and neurochemistry of apomorphine
14. Apomorphine for motor fluctuations and freezing in Parkinson's disease
15. Auto-oxidation of apomorphine
16. 2 and 6-hydroxydopamine
17. Iron-reducing, and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines
18. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
19. Dopamine-, and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells
20. Glia protect midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms
21. Physiology of transformed glial cells
22. A simple method for evaluation of superoxide radical production in neural cells under various culture conditions: Application to hypoxia
23. Apomorphine is a high potent free radical scavenger in rat brain mitochondrial fraction
24. Pharmacokinetics of apomorphine in parkinsonian patients
25. Re-examination, and further development of a precise and rapid dye method for measuring cell growth/cell kill
26. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding
27. Interactions of apomorphine with serum and tissue proteins
28. Levodopa: Is toxicity a myth?
29. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
30. Superoxide anion production during monoelectronic reduction of xenobiotics by preparations of rat brain cortex, microvessels, and choroid plexus
31. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects
32. Levodopa neurotoxicity: Experimental studies versus clinical relevance
33. Is levodopa toxic?
34. Toxic effects of L-DOPA on mesencephalic cell cultures: Protection with antioxidants
35. Toxic and protective effects of L-dopa on mesencephalic cell cultures
36. New pharmacotherapy for Parkinson's disease
37. Determination of apomorphine in rat plasma and brain by high-performance liquid chromatography with electrochemical detection
38. Motor response following repeated apomorphine administration is reduced in Parkinson's disease
39. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: Long-term follow-up in 18 patients
40. Extracellular toxicity of 6-hydroxydopamine on PC12 cells
41. Multiple actions of superoxide dismutase: Why can it both inhibit and stimulate reduction of oxygen by hydroquinones?
42. +-dependent GSH transport in HCEC
43. Mechanisms of apomorphine cytotoxicity towards rat glioma C6 cells: Protection by bovine serum albumin and formation of apomorphine-protein conjugates
44. Neurotoxicity of endogenous cysteinylcatechols
45. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species
46. Nigrostriatal neuronal death in Parkinson's disease: A passive or an active genetically-controlled process?
47. Free radicals and neurodegenerative diseases: Stress and oxidative damage
48. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: Evidence that astrocytes play an important role in antioxidative processes in the brain
49. Antioxidant defense of the brain: A role for astrocytes
50. Menadione toxicity in cultured rat cortical astrocytes
51. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid
52. Iron metabolism and Parkinson's disease